Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    AbCellera Biologics Inc.

    NASDAQ: ABCL · Real-Time Price · USD
    3.16
    -0.04 (-1.25%)
    At close: Jun 16, 2025, 3:59 PM
    3.15
    -0.35%
    Pre-market: Jun 17, 2025, 04:57 AM EDT

    AbCellera Biologics Statistics

    Share Statistics

    AbCellera Biologics has 298.49M shares outstanding. The number of shares has increased by 1.34% in one year.

    Shares Outstanding

    n/a
    		 298.49M

    Shares Change (YoY)

    n/a
    		 1.34%

    Shares Change (QoQ)

    n/a
    		 0.89%

    Owned by Institutions (%)

    n/a
    		 38.63%

    Shares Floating

    n/a
    		 223.95M

    Failed to Deliver (FTD) Shares

    n/a
    		 1,499,933

    FTD / Avg. Volume

    n/a
    		 32.57%

    Short Selling Information

    The latest short interest is 22.84M, so 7.65% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 22.84M

    Short % of Shares Out

    n/a
    		 7.65%

    Short % of Float

    n/a
    		 9.93%

    Short Ratio (days to cover)

    n/a
    		 9.36

    Valuation Ratios

    The PE ratio is -5.3 and the forward PE ratio is -5.65. AbCellera Biologics's PEG ratio is -0.68.

    PE Ratio

    n/a
    		 -5.3

    Forward PE

    n/a
    		 -5.65

    PS Ratio

    n/a
    		 29.91

    Forward PS

    n/a
    		 4.6

    PB Ratio

    n/a
    		 0.82

    P/FCF Ratio

    n/a
    		 -4.61

    PEG Ratio

    n/a
    		 -0.68
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for AbCellera Biologics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 9.81, with a Debt / Equity ratio of 0.06.

    Current Ratio

    n/a
    		 9.81

    Quick Ratio

    n/a
    		 9.81

    Debt / Equity

    n/a
    		 0.06

    Debt / EBITDA

    n/a
    		 -0.32

    Debt / FCF

    n/a
    		 -0.35

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $48,377.52

    Profits Per Employee

    n/a
    		 $-273,250

    Employee Count

    n/a
    		 596

    Asset Turnover

    n/a
    		 0.02

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 -37.54M

    Effective Tax Rate

    n/a
    		 18.73%

    Stock Price Statistics

    The stock price has increased by 3.27% in the last 52 weeks. The beta is 0.36, so AbCellera Biologics's price volatility has been higher than the market average.

    Beta

    n/a
    		 0.36

    52-Week Price Change

    n/a
    		 3.27%

    50-Day Moving Average

    n/a
    		 2.33

    200-Day Moving Average

    n/a
    		 2.66

    Relative Strength Index (RSI)

    n/a
    		 76.47

    Average Volume (20 Days)

    n/a
    		 4,605,239

    Income Statement

    In the last 12 months, AbCellera Biologics had revenue of 28.83M and earned -162.86M in profits. Earnings per share was -0.55.

    Revenue

    n/a
    		 28.83M

    Gross Profit

    n/a
    		 -68.17M

    Operating Income

    n/a
    		 -314.77M

    Net Income

    n/a
    		 -162.86M

    EBITDA

    n/a
    		 -204.15M

    EBIT

    n/a
    		 -301.15M

    Earnings Per Share (EPS)

    n/a
    		 -0.55
    Full Income Statement

    Balance Sheet

    The company has 156.32M in cash and 65.36M in debt, giving a net cash position of 90.96M.

    Cash & Cash Equivalents

    n/a
    		 156.32M

    Total Debt

    n/a
    		 65.36M

    Net Cash

    n/a
    		 90.96M

    Retained Earnings

    n/a
    		 116.93M

    Total Assets

    n/a
    		 579.23M

    Working Capital

    n/a
    		 689.58M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -108.56M and capital expenditures -78.4M, giving a free cash flow of -186.95M.

    Operating Cash Flow

    n/a
    		 -108.56M

    Capital Expenditures

    n/a
    		 -78.4M

    Free Cash Flow

    n/a
    		 -186.95M

    FCF Per Share

    n/a
    		 -0.64
    Full Cash Flow Statement

    Margins

    Gross margin is -236.42%, with operating and profit margins of -1091.69% and -564.83%.

    Gross Margin

    n/a
    		 -236.42%

    Operating Margin

    n/a
    		 -1091.69%

    Pretax Margin

    n/a
    		 -695.02%

    Profit Margin

    n/a
    		 -564.83%

    EBITDA Margin

    n/a
    		 -708.04%

    EBIT Margin

    n/a
    		 -1091.69%

    FCF Margin

    n/a
    		 -648.4%

    Dividends & Yields

    ABCL does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for ABCL is $10, which is 216.5% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $10

    Price Target Difference

    n/a
    		 216.5%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 4
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 1.25

    Piotroski F-Score

    n/a
    		 2

    Add to Watchlist